Lanosterol

Lanosterol

SCHEMBL14360758

CC(C)=CCCC(C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)C1CC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
USP2 O75604 2/20 1.00
ALDH1A1 P00352 2/20 1.00
CYP3A4 P08684 2/20 1.00
ALOX15 P16050 2/20 1.00
CRYAB P02511 2/20 1.00
LMNA P02545 1/20 1.00
PTGES O14684 4/20 0.79
FNTA P49354 1/20 0.74
FNTB P49356 1/20 0.74
CRYAA P02489 1/20 0.71
ACHE P22303 1/20 0.62
MEN1 O00255 1/20 0.61
PLA2G1B P04054 1/20 0.61
DNMT1 P26358 1/20 0.61
BLM P54132 1/20 0.61
KMT2A Q03164 1/20 0.61
ATG4B Q9Y4P1 1/20 0.61
HMGCR P04035 1/20 0.61
PREP P48147 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lanosterol SCHEMBL16994483 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL145834 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL14240642 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL14536063 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL2154745 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL145835 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL1696473 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL19194030 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL21348006 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL244737 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242538-A1 PanK Modulators and Methods Using Same UNIV YALE (US) 2023-08-03 US disclosed
US-20070259837-A1 Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-11-08 US disclosed
US-20070259837-A1 Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242538-A1 PanK Modulators and Methods Using Same PANK1, PANK2, PANK3 MAPT 818/4885USP2 2910/4885ALDH1A1 3646/4885
US-20070259837-A1 Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy UTRN, MTPN, NR3C1 MAPT 4082/4885USP2 3948/4885ALDH1A1 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.